BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 20060157)

  • 1. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-II mRNA-binding protein 3 expression in effusion cytology: a marker for metastatic adenocarcinoma cells and a potential prognostic indicator in gastric adenocarcinoma.
    Kim HJ; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
    Acta Cytol; 2014; 58(2):167-73. PubMed ID: 24457229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
    Rehnberg J; Zendehrokh N; Dejmek A
    Anal Quant Cytol Histol; 2007 Aug; 29(4):217-20. PubMed ID: 17879629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
    Reich R; Vintman L; Nielsen S; Kaern J; Bedrossian C; Berner A; Davidson B
    Diagn Cytopathol; 2005 Nov; 33(5):332-7. PubMed ID: 16240397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
    Hyun TS; Barnes M; Tabatabai ZL
    Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless.
    Simsir A; Fetsch P; Mehta D; Zakowski M; Abati A
    Diagn Cytopathol; 1999 Mar; 20(3):125-30. PubMed ID: 10086235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I; Oprescu FA; Rullo E; Ascoli V
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.
    Yan J; Wei Q; Jian W; Liu J; Tang H; Ge J; Zhou J; Zhao T
    Int J Clin Exp Pathol; 2014; 7(9):5810-8. PubMed ID: 25337222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
    Hafez NH; Tahoun NS
    J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.